- Preclinical
Animal Pharmacology Testing - GLP Toxicology
- Phase I
Dose Escalation - Phase II
- Phase III
INT230-6 (collaboration)
Colorectal Non-MSI High
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
+ Merck’s Keytruda (non-immunogenic “cold tumors”)
Sarcoma
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
+ BMS’ Yervoy (immunogenic cold)
Bile Duct
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
+ Keytruda (cold)
Pancreatic
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
+ Keytruda (cold)
Squamous Cell
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
+ Keytruda (patients who failed PD-1)
Breast
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
+ Yervoy
Liver
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
+ Yervoy
INT230-6 mTNBC
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
Fast Track Monotherapy
INT230-6 BC
pre-surgery
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
Monotherapy Pre-surgical Setting (local or regional disease)
INT33X
(Next Generation)
- Preclin
- GLP Toxicology
- Phase I
- Phase II
- Phase III
mTNBC = metastatic Triple Negative Breast Cancer
BC = Breast Cancer